BriefingIndustry newsIndustry briefingNEWSBayer agrees to pay $40m to resolve claims on three drugsBayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims Act linked to three drugs, Trasylol, Avelox and Baycol, the US Department of Justice said in a press statementnewsNovartis announces plans to spin off Sandoz businessNovartis has announced plans to completely spin off its generics and biosimilars division, Sandoz, to create a new publicly traded standalone firmBriefingFDA authorises Edgewise’s Phase II duchenne muscular dystrophy trialThe US FDA granted authorisation for Edgewise Therapeutics’ Phase II clinical trial of EDG-5506 for treating duchenne muscular dystrophy (DMD) in childrenIndustry newsIndustry briefing02/24/2024 03:46:44
Briefing
FDA authorises Edgewise’s Phase II duchenne muscular dystrophy trial
The US FDA granted authorisation for Edgewise Therapeutics’ Phase II clinical trial of EDG-5506 for treating duchenne muscular dystrophy (DMD) in children